Please make sure that HealthWell currently has a fund for your diagnosis/indication and that your medication is covered under that fund by visiting our Diseases and Medications listing. If we do not have a fund that currently covers your diagnosis, please check back as we frequently open and reopen programs as funding becomes available. The Foundation is able to help patients receiving treatment for indications for which we currently have an open fund. We can only assist with medications that have been prescribed to treat the disease/covered diagnosis. You will be asked to provide the Foundation with the patient’s diagnosis, which must be verified by a physician, nurse practitioner, or physician assistant’s signature. The patient must receive treatment in the United States.
Lambert-Eaton Myasthenic Syndrome
Status
ClosedThis fund is temporarily closed to new patients due to lack of sufficient funding. Please continue to visit our Disease Funds page often, as replenished funds reopen as quickly as possible. If you currently have a grant with HealthWell, your grant will remain active for the entire 12 month grant cycle or until you have exhausted your allocated grant amount, whichever comes first. You can continue to use your pharmacy card or submit requests for reimbursements during your designated grant cycle.
Assistance Type
Prescription Drug Copayor
Insurance premium (Medicare Part B only)
Maximum Award Level
Pharmacy Card Fund
YesMinimum Copay Reimbursement Amount
We encourage you to please use your HealthWell pharmacy card for any applicable charges as possible.
Minimum Premium Reimbursement Amount
Household Income Limit
500% of the Federal Poverty Level(adjusted for household size and high cost of living areas)
Treatments Covered
- Asceniv
- Bivigam
- Carimune Nf
- Diaminopyridine
- Firdapse
- Flebogamma Dif
- Gammagard
- Gammagard S/d Less Iga
- Gammaplex
- Guanidine
- Immune Globulin Intravenous (ivig)
- Octagam
- Panzyga
- Prednisone
- Privigen
- Rayos
- Ruzurgi
Fund Definition
Assistance with the prescription drugs and biologics used in the treatment of LEMS.
Grant Utilization
HealthWell estimates that patients use an average of $5,870 during their 12-month grant period for this disease area.
Do I Qualify?
HealthWell bases eligibility on an individual’s medical, financial and insurance situation. To qualify for HealthWell’s assistance, applicants must meet the following eligibility requirements:
-
-
To qualify for copayment assistance from HealthWell, you must have some form of health insurance (private insurance, Medicare, Medicaid, TriCare, etc.) that covers part of the cost of your treatment. Please note that in order to qualify for premium assistance through this fund, you must have Medicare Part B. The Foundation will refer patients without prescription insurance to other programs, such as manufacturer patient assistance programs.
-
HealthWell assists individuals with incomes up to 300-500% of the Federal Poverty Level. The Foundation also considers the number in a household and cost of living in a particular city or state. If you believe you qualify for assistance, you may begin the application process here.
-
If you are receiving treatment in the U.S. and have met the eligibility criteria as listed, you are ready to apply! Please note that you will be asked to provide a Social Security Number in order to create a grant. This information is gathered to eliminate duplicate applications and is kept secure and confidential.
About Lambert-Eaton Myasthenic Syndrome
According to the Muscular Dystrophy Association (MDA), LEMS is a rare neuromuscular disorder that weakens and fatigues the body’s voluntary muscles, usually causing weakness in the upper legs and hips. These proximal muscles (muscles closest to the body’s midline) are likely to fatigue with use, causing more prominent stiffness than actual weakness. As the legs are particularly affected, it may difficult to go climb stairs, run, walk or get out of a chair. Weakness and fatigue can fluctuate from day to day and stress, heat and lack of sleep make symptoms worse. Approximately 50 to 60 percent of LEMS cases are associated with an underlying disease, particularly small cell lung cancer. While the trigger for LEMS is unknown in people without cancer, it is estimated that about half of those with LEMS have or will develop cancer. People without cancer usually do well with treatment, but most continue to have symptoms. LEMS can be difficult to diagnosis since weakness in the legs, with or without arm weakness and fatigue, are common complaints in general. Source: Muscular Dystrophy Association
Additional Educational Resources
You may also visit our Resource List to view other copayment organizations that may provide assistance.
